Morgan Stanley Smith Osmotica Pharma. - Form 8.3 - Osmotica Pharamaceuticals plc

RVL Pharmaceuticals

25/03/2021 10:37

RNS Number : 4958T

Morgan Stanley Smith Barney LLC

25 March 2021

 

 

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

 

1.       KEY INFORMATION

 

Nameofpersondealing(Note1)
Morgan Stanley Smith Barney LLC
Companydealtin
OSMOTICA PHARAMACEUTICAL
Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate(Note2)
US$0.01 ORDINARY SHARES
Dateofdealing
24 March 2021

 

 

 

2.       INTERESTS AND SHORT POSITIONS

 

  (a)         Interests and short positions (following dealing) in the class of relevant security

               dealt in (Note 3)

Long
Short
Number
(%)
Number
(%)
(1)Relevantsecurities
1,633,081
2.6
0
0.00
(2)Derivatives (other than options)
0
0.00
0
0.00
(3)Options and agreements to purchase/sell
0
0.00
0
0.00
Total
1,633,081
2.6
0
0.00


 

 

(b)      Interests and short positions in relevant securities of the company, other than the   

           class dealt in (Note 3)

Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1)Relevantsecurities
0
0.00
0
0.00
(2)Derivatives (other than options)
0
0.00
0
0.00
(3)Options and agreements to purchase/sell
0
0.00
0
0.00
Total
0
0.00
0
0.00


 

 

 

1.       DEALINGS (Note 4)

(a)      Purchases and sales

 

Purchase/sale
Number of relevant securities
Price per unit (Note 5)
SALE
64
3.6109 USD

 

 

(b)      Derivatives transactions (other than options transactions)

 

Productname,
e.g.CFD
Natureoftransaction
(Note6)
Numberofrelevantsecurities
(Note7)
Priceperunit
(Note5)
N/A
N/A
N/A
N/A

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Productname,
e.g.calloption
Writing,selling,purchasing,varyingetc.
Numberofsecuritiestowhichtheoptionrelates(Note 7)
Exerciseprice
Type,e.g.American,Europeanetc.
Expirydate
Optionmoneypaid/receivedperunit(Note 5)
N/A
N/A
N/A
N/A
N/A
N/A
N/A

 

 

(ii)      Exercising

 

Productname,
e.g.calloption
Numberofsecurities
Exercisepriceper unit(Note5)
N/A
N/A
N/A

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Natureoftransaction
(Note8)
Details
Priceperunit
(if applicable) (Note 5)
N/A
N/A
N/A

 

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Fulldetailsofanyagreement,arrangementorunderstandingbetweenthepersondisclosing andanyotherpersonrelatingtothevotingrightsofanyrelevantsecuritiesunderanyoption referredtoonthisformorrelatingtothevotingrightsorfutureacquisitionordisposalofanyrelevantsecuritiestowhichanyderivativereferredtoonthisformisreferenced.Ifnone,this shouldbestated.
NONE

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Dateofdisclosure
25 March 2021
Contactname
Craig Horsley
Telephonenumber
+44 141 245-7736
IfaconnectedEFM,nameofofferee/offerorwithwhichconnected
NA
IfaconnectedEFM,statenatureofconnection(Note10)
NA

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
ISEJAMMTMTJTBIB